PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / adverse effects*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Biomarkers, Tumor
• Bleomycin / administration & dosage
• Bleomycin / adverse effects
• Bone Marrow / pathology
• Causality
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / adverse effects
• Doxorubicin / administration & dosage
• Doxorubicin / adverse effects
• Etoposide / administration & dosage
• Etoposide / adverse effects
• Female
• Hematopoietic Stem Cells / pathology
• Histiocytosis, Langerhans-Cell / chemically induced*
• Histiocytosis, Langerhans-Cell / diagnostic imaging
• Hodgkin Disease / complications
• Hodgkin Disease / drug therapy*
• Humans
• Langerhans Cells / pathology
• Laser Capture Microdissection
• Middle Aged
• Neoplasm Proteins / genetics
• Point Mutation
• Positron-Emission Tomography*
• Prednisone / administration & dosage
• Prednisone / adverse effects
• Procarbazine / administration & dosage
• Procarbazine / adverse effects
• Proto-Oncogene Proteins B-raf / genetics
• Reed-Sternberg Cells / pathology
• Temporal Bone / diagnostic imaging*
• Vincristine / administration & dosage
• Vincristine / adverse effects